American Century Companies Inc. Grows Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU)

American Century Companies Inc. lifted its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 9.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 159,822 shares of the company’s stock after purchasing an additional 13,421 shares during the quarter. American Century Companies Inc. owned 0.18% of Caribou Biosciences worth $254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. US Bancorp DE increased its stake in Caribou Biosciences by 3,524.2% during the 4th quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after purchasing an additional 26,467 shares in the last quarter. Thrive Wealth Management LLC bought a new stake in shares of Caribou Biosciences during the fourth quarter valued at approximately $51,000. Intech Investment Management LLC raised its holdings in Caribou Biosciences by 69.4% in the 4th quarter. Intech Investment Management LLC now owns 37,478 shares of the company’s stock worth $60,000 after acquiring an additional 15,352 shares during the last quarter. Barclays PLC lifted its position in Caribou Biosciences by 122.4% in the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after acquiring an additional 71,463 shares in the last quarter. Finally, Milestone Asset Management LLC boosted its stake in Caribou Biosciences by 5.6% during the 4th quarter. Milestone Asset Management LLC now owns 163,789 shares of the company’s stock valued at $260,000 after purchasing an additional 8,662 shares during the last quarter. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

NASDAQ CRBU opened at $0.87 on Monday. Caribou Biosciences, Inc. has a 1-year low of $0.66 and a 1-year high of $4.39. The stock has a market capitalization of $81.31 million, a price-to-earnings ratio of -0.53 and a beta of 2.36. The business’s fifty day moving average price is $1.09 and its 200-day moving average price is $1.61.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.01. The business had revenue of $2.08 million for the quarter, compared to analysts’ expectations of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. Equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Wall Street Analyst Weigh In

CRBU has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Wednesday, March 19th. Bank of America reduced their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.